Jian-jian Chen

Chengdu, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Journal: Alimentary pharmacology & therapeutics

Published: December 10, 2025

Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching study.

Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching study.

Journal: Frontiers in immunology

Published: November 17, 2025

Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: a multicenter study.

Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: a multicenter study.

Journal: International journal of surgery (London, England)

Published: September 16, 2025

Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation study.

Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation study.

Journal: EClinicalMedicine

Published: September 14, 2025

The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.

The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.

Journal: Academic radiology

Published: September 12, 2025

Engineered macrophage membrane-mimicking nanodrugs activate cGAS/STING pathway to reverse tumor immune suppression after incomplete radiofrequency ablation.

Engineered macrophage membrane-mimicking nanodrugs activate cGAS/STING pathway to reverse tumor immune suppression after incomplete radiofrequency ablation.

Journal: Journal of nanobiotechnology

Published: September 11, 2025

Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).

Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).

Journal: Hepatology (Baltimore, Md.)

Published: July 13, 2025

A Novel Self-Regulated, Non-Directional Magnetic Thermos-Brachytherapy 125I Seed Enhances Anticancer Efficacy by Rescuing Immune Escape.

A Novel Self-Regulated, Non-Directional Magnetic Thermos-Brachytherapy 125I Seed Enhances Anticancer Efficacy by Rescuing Immune Escape.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 05, 2025

Combination locoregional and systemic therapies in hepatocellular carcinoma.

Combination locoregional and systemic therapies in hepatocellular carcinoma.

Journal: The lancet. Gastroenterology & hepatology

Published: April 07, 2024

Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).

Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).

Journal: Journal of cachexia, sarcopenia and muscle

Published: March 14, 2024

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Journal: EClinicalMedicine

Published: January 10, 2024

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.

Journal: United European gastroenterology journal

Published: June 29, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026